Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624006 | 0.91 | LIPG (0.33) | NTRK1LIPG | |
| SCHEMBL13624001 | 0.88 | LIPG (0.33) | NTRK1LIPG | |
| SCHEMBL13624000 | 0.88 | LIPG (0.33) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL13624002 | 0.88 | GRM2 (0.33) | NTRK1LIPG | |
| SCHEMBL13624007 | 0.87 | GPR52 (0.35) | NTRK1LIPG | |
| SCHEMBL13624008 | 0.87 | CNR2 (0.38) | NTRK1LIPG | |
| SCHEMBL13623962 | 0.85 | LIPG (0.34) | PTGER4NTRK1LIPGVNN1 | |
| SCHEMBL13623970 | 0.84 | PTGER4 (0.32) | PTGER4LIPG | |
| SCHEMBL13846194 | 0.82 | LIPG (0.32) | LIPG | |
| SCHEMBL13624005 | 0.82 | GABRA5 (0.32) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | PTGER4 3944/4885TBXA2R 3246/4885PTGFR 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.